dc.contributor.author |
Asthana, Shalini |
|
dc.contributor.author |
Gupta, P K |
|
dc.contributor.author |
Chaurasia, Mohini |
|
dc.contributor.author |
Dube, Anuradha |
|
dc.contributor.author |
Chourasia, M K |
|
dc.date.accessioned |
2014-06-23T11:21:31Z |
|
dc.date.available |
2014-06-23T11:21:31Z |
|
dc.date.issued |
2013 |
|
dc.identifier.citation |
Expert opinion on Drug Delivery, 2013, 10(12), 1633-1651 |
en |
dc.identifier.uri |
http://hdl.handle.net/123456789/1293 |
|
dc.description.abstract |
Introduction: Targeted cargo delivery systems can overcome drawbacks associated with antileishmanials delivery, by defeating challenges of physiological barriers. Various colloidal particulate systems have been developed in the past; few of them even achieved success in the market, but still are limited in some ways.
Areas covered: This review is focused on the pathobiology of leishmaniasis, interactions of particulate systems with biological environment, targeting strategies along with current conventional and vaccine therapies with special emphasis on polymeric nanotechnology for effective antileishmanial cargo delivery.
Expert opinion:
The problems concerned with limited accessibility of chemotherapeutic cargos in conventional modes to Leishmania-harbouring-macrophages, their toxicity and resistant parasitic strain development; can be sorted out through target specific delivery of cargos. Vaccination is another therapeutic approach employing antigen alone or adjuvant combinations delivered by carrier means of a carrier, and can provide preventive measure against human leishmaniasis (HL). Therefore, there is an urgent need of designing site-specific antileishmanial cargo carriers for safe and effective management of HL. Amongst various colloidal carriers, polymeric particulate systems hold tremendous potential as an effective delivery tool by providing control over spatial and temporal distribution of cargos after systemic or localized administration along with enhancing their stability profile at a comparatively cost effective price leading to improved chances of commercial applicability. |
en |
dc.format.extent |
527374 bytes |
|
dc.format.mimetype |
application/pdf |
|
dc.language.iso |
en |
en |
dc.relation.ispartofseries |
CSIR-CDRI Communication No. 8523 |
en |
dc.subject |
Human leishmaniasis |
en |
dc.subject |
Passive Targeting |
en |
dc.subject |
Active Targeting |
en |
dc.subject |
Polymeric nano/micro-particles |
en |
dc.subject |
Immunotherapy |
en |
dc.subject |
Vaccines |
en |
dc.title |
Polymeric Colloidal Particulate Systems: Intelligent Tools for Intracellular Targeting of Antileishmanial Cargos |
en |
dc.type |
Article |
en |